Id |
Subject |
Object |
Predicate |
Lexical cue |
T62 |
0-6 |
Sentence |
denotes |
4.1.1. |
T63 |
8-49 |
Sentence |
denotes |
Hindrance of receptor recognition process |
T64 |
50-141 |
Sentence |
denotes |
The S protein of SARS-CoV-2 is cleaved by host proteases into two subunits, S1 and S2 [19]. |
T65 |
142-325 |
Sentence |
denotes |
The S1 subunit binds to the host cell surface receptor angiotensin-converting enzyme 2 (ACE2) for virus attachment, and the S2 subunit fuses the virus and the host cell membrane [19]. |
T66 |
326-714 |
Sentence |
denotes |
The investigation of the effect of CQ on ACE2 in VeroE6 cells showed that effective anti-SARS-CoV-2 concentrations of CQ had no significant effect on the synthesis and glycosylation of S protein on the surface of SARS-CoV, and although it had no significant effect on the cell surface expression of ACE2, CQ could destroy the glycosylation at the terminal glycosylation site of ACE2 [13]. |
T67 |
715-988 |
Sentence |
denotes |
Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1). |
T68 |
989-998 |
Sentence |
denotes |
Figure 1. |
T69 |
999-1117 |
Sentence |
denotes |
Schematic representation of the possible mechanisms of CQ/HCQ against CoVs replication and modulating immune response. |
T70 |
1118-1749 |
Sentence |
denotes |
CQ/HCQ may synergistically exert antiviral and immunomodulatory effects on COVID-19 through multiple mechanisms including hindering the receptor recognition process by influencing the affinity of ACE2 and S protein, and the affinity for sialic acid and ganglioside; inhibiting the membrane fusion process by suppressing endolysosome acidification; suppressing the p38 activation and affecting host defense machinery, and preventing MHC class II expression (block expression of CD154 on the surface of CD4 + T cell) and TLR signaling and reducing the production of cytokines through inhibiting the activation of T cells and B cells. |
T71 |
1750-2100 |
Sentence |
denotes |
ACE2, angiotensin-converting enzyme 2; COVID-19, coronavirus disease 2019; CQ, chloroquine; HCQ, hydroxychloroquine; CoVs, coronaviruses; MAPK, mitogen-activated protein kinase; MHC-II, major histocompatibility complex class II; TLR, toll-like receptor; cGAS, cyclic GMP-AMP synthase; IFN, interferon; IL, interleukin; TNF-α, tumor necrosis factor-α. |
T72 |
2101-2386 |
Sentence |
denotes |
In addition to protein membrane receptors, infection of host cells by HCoVs also relies on sialic acid-containing glycoproteins and gangliosides, which are used by a broad range of viruses as receptors, such as influenza [20] and HCoVs including SARS-CoV [21] and HCoV-OC43 [13,22,23]. |
T73 |
2387-2585 |
Sentence |
denotes |
A recent molecular structure analysis showed that SARS-CoV-2 not only uses ACE2 as a receptor, but also recognizes highly conserved gangliosides on the host cell surface through sialic acid [24,25]. |
T74 |
2586-2726 |
Sentence |
denotes |
CQ/HCQ binds sialic acids and gangliosides with high affinity, which can prevent the attachment of SARSCoV-2 S protein to gangliosides [25]. |
T75 |
2727-2834 |
Sentence |
denotes |
CQ had inhibitory effect on quinone reductase 2 (QR2) involved in the biosynthesis of sialic acids [26,27]. |
T76 |
2835-2986 |
Sentence |
denotes |
Hence, the mechanism of anti-CoV activity of CQ/HCQ may also be related to hindering the recognition process of sialic acid and ganglioside (Figure 1). |